We describe 17 non-intubated COVID-19 patients with severe hypoxemia for whom awake prone positioning was attempted. Although no significant adverse events related to prone positioning were observed, several patients did not tolerate long durations of prone positioning (median duration 75 min), or prone positioning for more than one session. Seven patients required intubation and invasive mechanical ventilation despite all patients improving their respiratory rate and oxygenation while in the prone position.
This study presents one of the first descriptions of awake prone positioning for COVID-19 patients with severe acute hypoxemic respiratory failure. Previous studies describing the use of prone positioning for non-intubated COVID-19 patients included patients with less severe hypoxemia.7 One recent study included patients with a similar degree of hypoxemia, but they received NIV in addition to prone positioning.6 In that report, it is difficult to distinguish if the physiologic effects observed are secondary to the prone positioning or the NIV. The strategy of NIV and prone positioning had a lower probability of requiring intubation (one of 15 patients, 7%) compared with the rate of intubation in the patients in our cohort (seven of 17 patients, 41%). Future studies will need to delineate if there is a role for awake prone positioning patients with acute severe hypoxemic respiratory failure who are not receiving positive pressure ventilation.
The allure of using awake prone positioning is to potentially mitigate the need for mechanical ventilation (either NIV or invasive ventilation) for patients at the highest risk of needing intubation. We demonstrate that awake prone positioning hypoxemic unintubated COVID-19 patients is feasible. Nevertheless, a significant number of patients may not tolerate prolonged courses of awake prone positioning or more than one session. This is despite all patients having an improvement in oxygenation and respiratory rate while in the prone position. In this cohort, 35% of patients had prone positioning durations less than 60 min and the most common reasons for intolerance were musculoskeletal pain or general discomfort. Recently published cohorts have limited descriptions of the duration, frequency, and protocols used for prone positioning.6,7,8 Moreover, the reduction in respiratory rate (a marker for work of breathing) was not sustained after resupination. A previous meta-analysis showed for invasively mechanically ventilated patients with moderate-to-severe ARDS that longer durations of prone positioning (> 12 hr) were required before the patients had a significant survival benefit.12 Given this observation, the clinical benefits of short prone positioning durations may be limited.
This study is also one of the first to systematically describe adverse events, in particular those complications that are known to be associated with prone positioning invasively ventilated patients. In this cohort, we did not observe any iatrogenic removal of lines or tubes associated with the act of prone positioning. Nor did we observe any pressure ulcers, aspiration events, or hemodynamic instability. Previous studies make no mention of the presence or absence of these important events.8 Moreover, five of our 17 (29%) of our patients were successfully and safely prone positioned (21 sessions) on a hospital ward with no additional monitoring. This highlights the potential for this therapy to be used safely on the hospital ward, particularly during a pandemic when ICU resources and ventilators may be strained. Nevertheless, the small sample size in this study precludes any strong conclusions regarding safety or the frequency of less common adverse events. Indeed, for potential serious adverse events that were not observed in this cohort of 17 patients, the upper limit of the 95% confidence interval for each adverse event frequency could be as high as 17.6%.13 Almost half the patients (47%) were kept fasting as a result of prone positioning and the need for potential intubation. Although not an adverse event, fasting patients for extended periods of time may be associated with malnutrition and delayed recovery.14 Future large randomized-controlled trials (e.g., NCT04350723 and NCT04402879) are required to determine if any potential clinical benefits outweigh the risks of these adverse events. The observations in this case series can help inform prone positioning protocol design for trials and guidelines.
This study must be interpreted within the context of its limitations. These include the small number of patients, selection bias by the providers who were choosing to prone position patients, and lack of a control group for comparison of outcomes. Also, a standardized prone positioning protocol was not used, which may have led to variability in clinicians’ approaches to duration and frequency of prone positioning. Only one patient received HFNC during a prone positioning session. All others in this cohort received oxygen by nasal prongs, face mask, or non-rebreather masks while undergoing prone positioning. Therefore, the results of this study should not be extrapolated to those undergoing prone positioning with HFNC or NIV, which could improve tolerability and physiologic effectiveness.5,6
In summary, awake prone positioning is a promising therapy for acute hypoxemic respiratory failure due to COVID-19. Nevertheless, there remain many questions about its clinical benefit, dosing, potential risks, and adverse events associated with prone positioning non-intubated patients. Strategies to increase the duration and tolerability of the prone position will likely be required before it can have a significant impact on patient outcomes. Randomized-controlled trials are needed to determine the efficacy of prone positioning on intubation avoidance, safety, and mortality.